Eli Lilly Lifts Q2 Revenue 48% to $23 Billion as Mounjaro Sales Jump 91%
Updated
Updated · Yahoo Finance · Aug 8
Eli Lilly Lifts Q2 Revenue 48% to $23 Billion as Mounjaro Sales Jump 91%
3 articles · Updated · Yahoo Finance · Aug 8
Summary
$23 billion in second-quarter revenue marked a 48% year-over-year surge for Eli Lilly, driven by booming demand for its GLP-1 franchise.
Mounjaro sales climbed 91% to $9.9 billion, while weight-loss drug Zepbound brought in $4.9 billion, up 46% from a year earlier.
Tirzepatide remains Lilly’s main growth engine, with approvals spanning diabetes, weight loss and obstructive sleep apnea as GLP-1 drugs expand into new disease markets.
Lilly is also building its next wave of growth through oral GLP-1 drug Foundayo and retatrutide, which posted strong phase 3 data ahead of a planned approval filing in Q1 2027.